TMC welcomes Simon Estcourt as new Chief Executive Officer (CEO) to spearhead next phase of development

TMC Pharma Services Ltd., an established global product development and clinical research organisation (CRO) headquartered in Hampshire UK, is pleased to announce the appointment of Simon Estcourt as its new CEO, effective 7 May 2024.

TMC is a global clinical research organisation dedicated to supporting the progression of life-saving treatment solutions for diseases that are often neglected.

We’re a specialised and experienced full-service CRO providing world-class support to pharma/biotech companies. To maximise success, we offer our clients a broad range of services with a focused and tailored approach for all their drug development requirements.

global partner

A Message From Our CEO

TMC is delighted to announce the appointment of Simon Estcourt as our new CEO.

With over 25 years of strategic leadership experience, Simon is highly qualified to spearhead our global expansion, having nurtured partnerships with organisations that have helped thousands of patients worldwide.

He commented: ‘I’m very excited to join such a well-regarded in-house team of experienced experts and specialist Associates. Together, we can maximise TMC’s countless strengths and make the most of emerging opportunities.’

Simon succeeds Julie Matthews, who co-founded TMC with her physician husband, Mike Matthews, in 2000, to provide drug development support to pharma/biotech companies in the orphan, rare and oncology disease space.

‘Simon shares our values and ambition and I have no doubt he will enable TMC to continue extending its reach by capitalising on the company’s exceptional services,’ Julie added.

Read more about Simon’s professional background and what this exciting news means for our clients.

Simon Estcourt

Our Expertise

Our development support activities span the early pre-clinical phase right through to post-marketing. We provide all the functions of a fully resourced pharmaceutical company, providing ‘bolt-on’ services that complement a client’s in-house resource, enabling them to access all the development capability appropriate for each stage of their project.


We only employ knowledgeable and trusted Associates who have worked in the pharma industry for at least 15 years. These experts can draw on their extensive experience to guide programmes and strategies — providing flexible, integrated and cost-effective solutions to meet our clients’ needs.


We specialise in orphan, rare and oncology diseases. Rare diseases affect 1 in 10 people, meaning more than 350 million people worldwide*. These people are often overlooked as there are significant challenges in the design and execution of clinical trials therapeutics. That’s why it’s our mission, indeed our passion, to offer drug development support in these disease areas.



No two drug development programmes are the same — just as no two patients are the same. We help our clients understand the patient journey, facilitating their drug development pathway to bring treatments to market quickly and efficiently.

watch our latest recorded


Exploring the Differences in Medical Services for Rare Diseases

Milestones in Numbers

Championing the patients living with life-limiting orphan and rare diseases

0 years
since TMC was founded
associates worldwide
paediatric investigation plans (PIP)
orphan drug designation (ODD) applications